Saturday, July 26, 2014





Bristol-Myers ends hepatitis C drug development


February 16. 2013 6:41PM
Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) Drugmaker Bristol-Myers Squibb Co. says it has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure.


The New York company said it decided to discontinue development of the drug in the interest of patient safety.


The patient's heart failure prompted Bristol-Myers to voluntarily suspend a mid-stage study of the drug on Aug 1.


The U.S. Food and Drug Administration subsequently placed the drug on a clinical hold.


Nine patients, including the one who died, were hospitalized. Two remain under hospital care.


The company identified heart and kidney toxicity as a key factor.


Bristol-Myers says it is working with the FDA to monitor the patients involved in the study.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds